First-line treatment of advanced ALK-positive non-small-cell lung cancer

Shipra Gandhi
Hongbin Chen
Yujie Zhao
Grace K Dy

1Department of Internal Medicine, State University of New York, 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

Abstract: Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within the US and worldwide. There have been major treatment advances in NSCLC over the past decade with the discovery of molecular drivers of NSCLC, which has ushered in an era of personalized medicine. There are several actionable genetic aberrations in NSCLC, such as epidermal growth factor receptor and anaplastic lymphoma kinase (ALK). In 3%–7% of NSCLC, a chromosomal inversion event in chromosome 2 leads to fusion of a portion of the ALK gene with the echinoderm microtubule–associated protein-like 4 (EML4) gene. The constitutive activation of the ALK fusion oncogene renders it vulnerable to therapeutic intervention. This review focuses on the first-line treatment of advanced ALK-positive NSCLC using ALK inhibitors. Crizotinib was the first agent proven to be efficacious as first-line treatment for ALK-positive NSCLC. However, acquired resistance inevitably develops. The central nervous system is a sanctuary site that represents a common site for disease progression as well. Hence, more potent, selective next-generation ALK inhibitors that are able to cross the blood–brain barrier have been developed for treatment against crizotinib-resistant ALK-positive NSCLC and are also currently being evaluated for first-line therapy as well. In this review, we provide summary of the clinical experience with these drugs in the treatment of ALK-positive NSCLC.

Keywords: non-small-cell lung cancer, ALK, first line, crizotinib, pemetrexed

Introduction

Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within the US and worldwide. The estimated number of new cases of lung cancer in 2015 is approximately 220,000 in the US alone, with deaths from the disease estimated at 158,000.1,2 Majority of patients with NSCLC are generally diagnosed in advanced stage with limited overall survival (OS) benefit from cytotoxic chemotherapy as the only systemic treatment modality option until the turn of the 21st century. Before the turn of this century, the treatment of stage IV NSCLC with a platinum-based doublet backbone remained relatively unchanged for decades.3 Chemotherapy provides modest improvements in survival for advanced NSCLC, but the 5-year survival rate is dismal at <5%.

Recent advances in the understanding of the complex biology of NSCLC and identification of specific genetic and molecular subgroups enabled the development of specific inhibitors to target oncogenic driver mutations. This underlies the basic approach toward precision medicine in which NSCLC is at the forefront, with the goal to improve survival outcomes of patients using therapies predicted to be most efficacious based on the genetic characteristics of the underlying disease and the individual patient.4
There are multiple oncogenic aberrations described to date in NSCLC. In 2007, ALK was identified as an oncogenic target in NSCLC serendipitously at the time of clinical development of a multikinase inhibitor whose spectrum of activity included ALK. This resulted in an unprecedented swift timeline toward accelerated US Food and Drug Administration (US FDA) approval in 2011 of the first targeted therapy against ALK.

**ALK-positive NSCLC**

**The EML4-ALK fusion protein**

In a small subset of NSCLC tumors, a chromosomal inversion event leads to fusion of a portion of the ALK gene with the echinoderm microtubule–associated protein-like 4 (EML4) gene. This inversion in chromosome 2 juxtaposes the 5′ end of the EML4 gene with the 3′ end of the ALK gene, resulting in the novel fusion oncogene EML4-ALK (Figure 1 shows the formation of the EML4-ALK fusion oncogene). The resulting chimeric protein, EML4-ALK, contains an N-terminus with coiled–coiled domain that mediates oligomerization derived from EML4 and a C-terminus containing the entire intracellular tyrosine kinase domain of ALK. The resulting EML4-ALK fusion protein is thus constitutively activated and transforming, and this fusion oncogene rearrangement defines a distinct clinicopathologic subset of NSCLC.

Currently, immunohistochemistry (IHC) plays a role as a screening modality for ALK rearrangement to select patients who may benefit from ALK-directed therapy. It is a rapid and relatively inexpensive method for diagnosing ALK-rearranged NSCLC. However, commercially available ALK antibodies lack the sensitivity to specifically detect the EML4-ALK fusion protein. The sensitivity and specificity of IHC ALK testing ranges from 67% to 100% and from 93% to 100%, respectively, using fluorescent in situ hybridization (FISH) as the standard procedure. Several authors have recommended a two-tiered approach, whereby patients initially be screened with IHC and those with faint, moderate, or intense staining be tested by FISH for confirmation of ALK positivity. Another modality developed to capture ALK fusion transcripts, and which has been confirmed to be a reliable technique for the diagnosis of EML4-ALK is multiplex reverse transcription-polymerase chain reaction (RT-PCR). An advantage with RT-PCR is that it is free from subjectivity in analysis, unlike IHC and FISH. Considering the higher sensitivity associated with RT-PCR for detecting ALK rearrangements in NSCLC, some studies have recommended to include it for ALK inhibitor treatment in the prospective clinical trials. However, it is limited by requirement for fresh frozen tissue samples for optimal testing conditions, and its validation and reproducibility in conventional formalin-fixed paraffin-embedded tissue sections can be challenging. FISH has been approved as a companion diagnostic tool by the US FDA. It is currently considered as a gold standard test for the presence of ALK rearrangement. However, FISH is time consuming and there exist multiple variants of EML4-ALK rearrangements like RNA editing abnormalities associated with intron abnormalities, which FISH is not able to detect. Patients with ALK rearrangements have been observed to show excellent response to ALK-targeted therapies, such as crizotinib, ceritinib, and alectinib; hence, it is important to not miss any cases and develop a sensitive and standardized approach. Next-generation sequencing (NGS) is an upcoming diagnostic technique for allowing comprehensive sequencing of entire genomes, exomes, and transcriptomes. NGS is able to detect EML4 and ALK genes that are separated by small rearrangements that prevent detection by FISH assay. A study by Ali et al showed that NGS may be more sensitive in detecting ALK rearrangements than FISH in lung cancer. Hence, in light of this data, there is a need to reconsider if FISH by itself is sufficient as standard modality for detecting ALK rearrangements and basing treatment decisions on its results.

Since the discovery of the first EML4-ALK fusion oncogene in 2007, nearly 30 specific variants of EML4-ALK have been reported to date, with exon 20 of ALK typically as the first exon fused to different exons of EML4 due to variable break points that result in different truncations of the EML4 partner. Rare ALK fusion variants with other gene partners have also been described in lung-cancer specimens, namely, TRK, TFG, KIF5B, HIP1, KLC1, and STRN. Majority of these fusion variants also contain exon

Figure 1 A chromosomal inversion in chromosome 2 juxtaposes the 5′ end of the EML4 gene with the 3′ end of the ALK gene resulting in the fusion oncogene EML4-ALK.

Notes: The resulting chimeric protein, EML4-ALK, contains an N-terminus derived from EML4 and a C-terminus containing the intracellular tyrosine kinase domain of ALK.

Abbreviations: EML4, echinoderm microtubule–associated protein-like 4; ALK, anaplastic lymphoma kinase.
Clinicopathologic and radiologic characteristics of patients with EML4-ALK fusion oncogene

EML4-ALK fusion and other ALK rearrangements occur in 3%–7% of patients with NSCLC (henceforth referred to as “ALK-positive” lung cancer).20–22 On the basis of the global estimate of 1.8 million new lung-cancer cases in 2012,23 it can be anticipated that there are at least 60,000 patients with newly diagnosed “ALK-positive” NSCLC worldwide. Tumors that contain the EML4-ALK fusion oncogene or its variants are associated with specific clinical features, including never or light-smoking history, younger age, and adenocarcinoma with signet ring or acinar histology. Generally, the ALK gene rearrangements are mutually exclusive of epidermal growth factor receptor (EGFR) or KRAS mutations.24 Radiologic features that appear to be associated with ALK+ status include central tumor location, lack of pleural tail sign, and large pleural effusion.25

ALK-positive NSCLC appears to be particularly sensitive to pemetrexed chemotherapy. In a retrospective study of 89 eligible patient cases conducted to explore whether the progression-free survival (PFS) with pemetrexed differs between ALK-positive and other major molecular subtypes, Camidge et al26 described that with pemetrexed used as first-line treatment in 48%, median PFS (mPFS) was 5.5 months (95% confidence interval [CI]: 1–9) in EGFR-mutant, 7 months (1.5–10) in KRAS-mutant, 9 months (3–12) in ALK-positive, and 4 months (3–5) in EGFR/KRAS-/ALK-WT (wild type). In a multivariate analysis adjusting for all the variables, the only variable associated with prolonged PFS on pemetrexed was ALK positivity (hazard ratio [HR] 0.36 [95% CI: 0.17–0.73], P=0.0051). Thus, the mPFS among 19 ALK-positive patients who received different pemetrexed-containing regimens as first-, second-, or fourth-line therapy was 9 months, exceeding that of 37 ALK/EGFR/KRAS-negative patients by 5 months. Similarly, in a study by Lee et al27 of patients with advanced NSCLC between 2007 and 2010 who were screened for EGFR mutations and ALK rearrangements, the efficacy of pemetrexed in 15 patients with ALK-positive were compared to 80 patients with ALK-negative (EGFR-mutant or -WT for both ALK and EGFR) NSCLC. The overall response rate (ORR) was superior in ALK-positive patients compared with EGFR-mutant or -WT patients (46.7% versus 4.7% versus 16.2%, P=0.001). The TTP (time to progression) among ALK-positive patients was longer than EGFR-mutant or -WT patients (9.2 versus 1.4 versus 2.9 months, P=0.001). ALK positivity alone was observed to be a significant predictor for ORR (HR =0.07, 95% CI: 0.01–0.32; P=0.001) and TTP (HR =0.44, 95% CI: 0.24–0.80; P=0.007). ALK positivity was independently significant regardless of treatment line (HR =0.43, 95% CI: 0.24–0.77; P=0.005). Hence, the TTP among 15 ALK-positive patients who had received single-agent pemetrexed in the second-line setting and beyond was 9.2 months; in contrast, the median TTP of 37 ALK-negative, EGFR-WT controls was only 2.9 months. The study suggested that ALK positivity was independently predictive of pemetrexed efficacy in NSCLC patients.27

Another multicenter retrospective analysis28 of PFS compared 121 ALK-positive patients versus 266 patients with advanced, ALK-negative, EGFR-WT NSCLC (79 with KRAS mutations and 187 with WT KRAS) treated with pemetrexed-based chemotherapy. This study is the largest retrospective analysis to date of ALK-positive and ALK-negative patients treated with pemetrexed-based chemotherapy. The PFS of all pemetrexed-based regimens was similar among ALK-negative and ALK-positive patients, except in the specific setting of first-line platinum/pemetrexed where there was statistically significant difference in mPFS of 8.5, 4.1, and 5.4 months in ALK-positive/KRAS and EGFR WT, ALK and EGFR-WT/KRAS-mutant, and ALK-/EGFR-/KRAS-WT patients, respectively. No difference in PFS was observed between ALK-positive and ALK-negative patients among patients with a never or light-smoking history (0–10 pack-year smoking history) treated with first-line platinum/pemetrexed. Among the never/light-smoking patients, the PFS on first-line platinum/pemetrexed may be prolonged regardless of ALK status. The analysis demonstrated that ALK-positive patients do not have a longer PFS on pemetrexed-based chemotherapy compared with ALK-negative controls, except in the setting of first-line platinum/pemetrexed combinations. It was concluded that the PFS on all pemetrexed regimens including first-line platinum/pemetrexed is similar between ALK-positive and ALK-negative patients within the subset of never or light-smoking patients. This finding reaffirms the previously known observations that smoking status influences treatment outcomes to therapy beyond that determined by the genotype.28 Nonetheless, the efficacy and toxicity profile favored the use of the platinum/pemetrexed combination as a comparator arm for the initial registrational study evaluating first-line therapy in this patient population.

Approved ALK inhibitors

The constitutive activation of the ALK fusion oncogene renders it vulnerable to therapeutic intervention. Figure 2
shows the constitutive activation of ALK tyrosine kinase due to aberrant expression of ALK, leading to downstream signaling pathways that lead to cell proliferation and survival. In the seminal paper described by Soda et al., inhibition of ALK induced cell death in cells expressing this fusion protein.

Treatment of EML4-ALK transgenic mice in vivo with ALK inhibitors results in tumor regression, supporting the notion that ALK-driven lung cancers are highly dependent on the fusion oncogene.

Two tyrosine kinase inhibitors, crizotinib and ceritinib, have established roles in the treatment of ALK-positive NSCLC, and additional agents are under development.

**Crizotinib**

Crizotinib (also known as PF-02341066) is a multitargeted small-molecule ALK inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition (c-MET) growth factor receptor tyrosine kinase. In addition to c-MET in cell-based assays, crizotinib also demonstrates nanomolar inhibition of ROS1, RON as well as ALK. As alluded to earlier, its accelerated approval for ALK-positive NSCLC was based on impressive Phase I clinical data initially published in 2010 by Kwak et al. and later updated by Camidge et al. in 2012.

**Trials: crizotinib in ALK-positive NSCLC**

**Phase I trials**

The Phase I study PROFILE 1001 initially included 37 patients with various advanced stage tumors, including colorectal cancer (six patients), sarcoma (four patients), and NSCLC (three patients), refractory to standard treatments, aimed to assess the maximum tolerated dose of crizotinib. Given the important activity of crizotinib in two patients with NSCLC with ALK rearrangement, this Phase I study was extended in this particular molecular genotype. The extension of this Phase I trial was published in October 2010 in the *New England Journal of Medicine*. After screening 1,500 patients with NSCLC in search of ALK rearrangement by FISH, the investigators identified and included 82 patients with advanced ALK-positive NSCLC. All enrolled patients received oral crizotinib at a dose of 250 mg twice daily in 28-day cycles, with tumor response measured every 2 months using Response Evaluation Criteria in Solid Tumors. At 6.4 months of treatment (median duration of treatment), 57% of patients had objective response of either partial (PR) or complete response (CR) (PR in 46 patients and CR in one patient) and 33% had stable disease. The Phase I study was further expanded to evaluate 143 patients. Approximately 60.8% (95% CI: 52.3–68.9) had an objective response (87 of 143 patients), including three CRs and 84 PRs. The median duration of response was 49.1 weeks (95% CI: 39.3–75.4). This response is largely independent of sex, age, condition, and the number of previous treatments. The mPFS was 9.7 months (95% CI: 7.7–12.8) and the median duration of response was 49 weeks.

**Phase II trials**

A noncomparative Phase II multicenter single-arm trial (PROFILE 1005) investigated the efficacy and safety of crizotinib administered to patients with ALK-positive
advanced NSCLC progressing after chemotherapy. The majority were women (53%), nonsmokers (65%), diagnosed with adenocarcinoma (92%), having an Eastern Cooperative Oncology Group (ECOG) scale of performance status of 0–2 (83%), and received ≥2 lines of chemotherapy (85%). As of the data lock on January 1, 2012, 901 ALK-positive NSCLC patients were enrolled, and all received crizotinib therapy.\(^{38}\)

Efficacy data reported on the mature population of 261 patients enrolled and treated by February 2011 showed that the observed ORR was 59.8% (n=155) for 259 patients who were evaluable for response, with an mPFS of 8.1 months.

Hence, the results of this Phase II study confirmed the results in PROFILE 1001, showing that crizotinib demonstrated a benefit in response rate and PFS with good tolerance in this group of previously treated ALK-positive patient population. On the basis of the response rates in the Phase I and II studies, the US FDA granted accelerated approval to crizotinib to treat patients with advanced NSCLC harboring ALK rearrangements in 2011.\(^{35}\) The study was later extended to Phase III trials to assess the benefit of crizotinib in patients with advanced stage NSCLC with ALK rearrangement.

A Phase II randomized chemoradiation study (NCT01822496) is currently ongoing to evaluate the role of crizotinib in the treatment of locally advanced stage III ALK-positive NSCLC.\(^{34}\) This Phase II randomized study compares standard chemoradiation to 60 Gy versus 12 weeks of induction therapy with crizotinib in EML4-ALK-translocated adenocarcinoma. Patients who did not achieve either PR or CR after 6 weeks will immediately receive conventional concurrent chemoradiation therapy. Otherwise, chemoradiation will be started 2 weeks after completion of induction therapy. The primary endpoint is PFS. The study will accrue an estimated 234 patients.

**Phase III trials**

A randomized Phase III trial was designed to compare crizotinib to standard second-line therapy, PROFILE 1007 is a randomized Phase III trial consisting of 347 patients with locally advanced or metastatic ALK-positive NSCLC previously treated with platinum-based chemotherapy. The patients were randomized into two arms to receive crizotinib or standard second-line chemotherapy: pemetrexed or docetaxel. The study was conducted at 105 sites in 21 countries. The primary endpoint was PFS and the secondary endpoint was OS. Crizotinib demonstrated superiority over docetaxel and pemetrexed; the mPFS was 7.7 months in the crizotinib arm versus 3 months in the chemotherapy arm (\(P<0.0001\)). Comparing each drug separately, the mPFS was 7.7 months in the crizotinib arm versus 4.2 months in the pemetrexed arm (\(P=0.0004\)); versus 2.6 months in the docetaxel arm (\(P<0.0001\)). No difference was observed in OS between the two groups (23.6 months with crizotinib versus 22.8 months with chemotherapy; HR, 1.02; \(P=0.54\)), likely owing to crossover of patients from chemotherapy to crizotinib. The response rate to crizotinib was almost triple compared with that of chemotherapy: 65.3% in crizotinib arm versus 19.3% in the chemotherapy arm (\(P<0.0001\)). Comparing crizotinib with each drug separately, the response rate to crizotinib was 65.7% versus 29.3% in the pemetrexed arm; versus 6.9% in the docetaxel arm. The safety profile was acceptable and the quality of life was higher for patients treated with crizotinib (\(P<0.0001\)). This Phase III randomized trial solidified the role of crizotinib, then to become the standard second-line treatment after platinum-based chemotherapy, in patients with ALK-positive NSCLC.\(^{37}\)

Given the impressive clinical activity outlined earlier in the salvage therapy settings, establishing the role of crizotinib as first-line therapy in advanced ALK-positive NSCLC was imperative. A multicenter, randomized open-label Phase III trial (PROFILE 1014) was conducted by Solomon et al\(^{38}\) comparing crizotinib with chemotherapy in 343 patients with advanced treatment naïve ALK-positive nonsquamous NSCLC. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or chemotherapy (pemetrexed plus cisplatin/carboplatin): 172 to crizotinib and 171 to chemotherapy. Crossover to crizotinib after disease progression was permitted for patients receiving chemotherapy. The primary endpoint was PFS. PFS was significantly longer with crizotinib than with chemotherapy (mPFS, 9.2 months versus 7.0 months) (95% CI: 6.8–8.2) (HR for progression or death with crizotinib, 0.6; 95% CI: 0.45; 0.75) versus 2.6 months in the docetaxel arm. The safety profile was acceptable and the quality of life was higher for patients treated with crizotinib (\(P<0.0001\)). Objective response rates were 74% and 45%, respectively (\(P<0.0001\)). Crizotinib was superior to standard first-line pemetrexed plus cisplatin chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.\(^{34}\) The HR favored crizotinib across most subgroups, defined according to the stratification factors. Crizotinib treatment was also associated with a significantly higher response rate and greater improvements in patient-reported measures of renal functioning, key lung-cancer symptoms (cough/dyspnea/chest pain and fatigue), and global quality of life.\(^{38}\) This study demonstrated superior outcome with crizotinib over pemetrexed plus platinum (carboplatin/cisplatin) chemotherapy as first-line therapy in patients with previously untreated advanced ALK-positive NSCLC and has defined the role of ALK inhibitors in the first-line setting. Its role in the adjuvant setting is currently being evaluated in the Phase III ALCHEMIST treatment trial, randomizing...
an estimated 378 patients with resected stage IB-IIIA ALK-positive NSCLC to either crizotinib or placebo (NCT02201992).

Ceritinib
Ceritinib (also known as LDK378) is a second-generation ALK inhibitor that is approximately 20 times more potent than crizotinib. It is currently approved for patients unable to tolerate crizotinib or with crizotinib-resistant ALK-positive NSCLC. Preclinical studies suggested that ceritinib had significant activity against cells that were either sensitive or resistant to crizotinib, including resistant tumors with the most common L1196M and G1269A resistance mutations. After the maximum tolerated dose was established in the Phase I (ASCEND-1) study, ceritinib was studied in a dose expansion cohort of NSCLC patients with ALK rearrangement. Results from that expansion cohort were updated at the 2014 American Society of Clinical Oncology meeting. A total of 246 patients with ALK-positive NSCLC were treated with ceritinib at a dose of 750 mg once daily, which necessitated at least one dose reduction in nearly 60% of the patients due to adverse events. The objective response rate was 58% overall, 55% in 163 patients who had prior crizotinib treatment, and 66% in 83 ALK inhibitor-naive patients. The median duration of response (9.7 months) in the entire cohort had not yet been reached in ALK inhibitor-naive patients and was reached in 7.4 months in those with prior crizotinib treatment. The mPFS for the entire cohort was 8.2 months, including 6.9 months for those previously treated with an ALK inhibitor and not yet reached (lower bound of 95% CI is 8.3 months) for those who had not previously received an ALK inhibitor. On the basis of these findings, ceritinib was approved by the US FDA in April 2014 for patients who have progressed on or are intolerant of crizotinib. Indeed, sequential crizotinib and ceritinib use achieves a combined mPFS of 17 months with ORR of 55% (24/44 patients). As the recommended Phase II dose of 300 mg twice daily required eight capsules per dose (20 and 40 mg preparation), a pharmacology study was conducted (JPJ28927) to evaluate bioequivalence with the 150 mg capsule preparation. The pharmacokinetic parameters were similar, and no food effect was seen with the 150 mg capsules. Efficacy results were as expected, with objective response rate confirmed in 60%. US FDA had granted breakthrough-therapy designation to ceritinib for ALK-positive advanced NSCLCs, which have progressed to crizotinib in June 2013, with approval being expected soon. Japan was the first country to approve the use of ceritinib in ALK-positive NSCLC in July 2014. ALEX study is a head-to-head randomized Phase III (NCT02075840) trial that was started in August 2014 to compare ceritinib versus crizotinib as first-line treatment in ALK-positive NSCLC. Approximately 286 patients will be enrolled to this ongoing trial.

Alectinib
Alectinib (also known as CH542802/RO542802) is a highly potent-selective ALK inhibitor, with activity against L1196M gatekeeper mutation as well as other secondary mutations such as G1269A. Results from the first-inhuman Phase I/II study with alectinib in a Japanese population of crizotinib-naive patients with ALK-positive advanced NSCLC were first reported by Seto et al. Seventy patients (24 in the Phase I study and 46 in the Phase II study) were enrolled. In the Phase II portion of the study, 43 of 46 (93.5%) patients achieved an objective response (93.5%) including two CRs (4.3%) and 41 PRs (89.1%). The mean duration of treatment was 14.8 months, and at 1 year of follow-up, the median PFS had not been reached. Another Phase I/II study was conducted in either crizotinib-pretreated or -intolerant ALK-positive advanced NSCLCs patients. Overall, 44 of 47 patients were assessable for activity in the Phase I study, with an ORR of 55% (24/44 patients). As the recommended Phase II dose of 300 mg twice daily required eight capsules per dose (20 and 40 mg preparation), a pharmacology study was conducted (JPJ28927) to evaluate bioequivalence with the 150 mg capsule preparation. The pharmacokinetic parameters were similar, and no food effect was seen with the 150 mg capsules. Efficacy results were as expected, with objective response rate confirmed in 60%. US FDA had granted breakthrough-therapy designation to alectinib for ALK-positive advanced NSCLCs, which have progressed to crizotinib in June 2013, with approval being expected soon. Japan was the first country to approve the use of alectinib in ALK-positive NSCLC in July 2014. ALEX study is a head-to-head randomized Phase III (NCT02075840) trial that was started in August 2014 to compare alectinib versus crizotinib as first-line treatment in ALK-positive NSCLC. Approximately 286 patients will be enrolled to this ongoing trial.

Special population: treatment of intracranial metastases in ALK-positive NSCLC
The treatment of ALK-positive NSCLC is often complex due to the frequent occurrence of brain metastases: initial occurrence of brain metastasis has been reported in 15%–35% of cases and, over the course of first-line therapy with either crizotinib or chemotherapy, the frequency of brain metastases can increase to 60%. Brain metastases are associated with many complications: some of these are neurocognitive, psychological, physical impairments, severe comorbidity, and a decreased life expectancy.
Pemetrexed has been used in combination with other chemotherapy for the treatment of intracranial metastases in NSCLC. Although clinical activity has been reported, the distribution of pemetrexed to the central nervous system (CNS) is limited and might result in low efficacy for CNS metastases.

While crizotinib has anecdotal activity against brain metastasis, it is generally viewed to have limited role against CNS metastases given its poor penetration against the blood–brain barrier as manifested in low cerebrospinal fluid concentration. Indeed, the CNS is a frequent site of disease progression, manifesting as either parenchymal or leptomeningeal metastases. Nonetheless, continued crizotinib administration after radiotherapy for isolated CNS progression was a feasible approach utilized prior to the availability of second-generation ALK inhibitors.

The Phase I ASCEND-1 study was instrumental in demonstrating the efficacy of ceritinib for intracranial metastases in ALK+ NSCLC. In a subset analysis, 124 out of total population of 246 had brain metastases at study entry. Among these 124 patients, 98 had been treated by an ALK inhibitor before, and 26 were ALK inhibitor treatment-naive. ALK inhibitor-naive patients with CNS metastases treated with ceritinib experienced an ORR of 69% and an mPFS of 8.3 months. In comparison, in patients previously treated with another ALK inhibitor, the ORR was 50% and the mPFS was 6.7 months. The intracranial response rate for patients with measurable brain metastases at baseline was 40.0% in patients who had received previous ALK inhibitor therapy, while this was 75% in ALK inhibitor-naive patients.

Alectinib is also another CNS-penetrant ALK inhibitor and its activity against brain metastases in crizotinib-resistant ALK-positive patients was elucidated early in the dose-escalation portion of the Phase I/II AF-002JG study. Out of 47 patients enrolled in the Phase I portion, 21 patients had CNS metastases at baseline. Approximately 52% of these patients had an objective response. Of four patients who had not had brain radiotherapy, two had a best CNS response of CR, one had PR, and one had stable disease. Of nine patients with measurable baseline CNS lesions, five had PR, two had stable disease, and two had progression disease, one of whom had pseudoprogression due to radiation necrosis. This clinical phenomenon needs to be recognized as it is difficult to distinguish from true disease progression and correct classification is required to avoid discontinuation of ALK inhibitor therapy, particularly if there is no extracranial disease progression.

Acquired resistance to ALK inhibitors

Approximately 30% of ALK-positive advanced NSCLC patients show intrinsic resistance to crizotinib. Moreover, despite initial response to treatment, all patients who initially respond to treatment eventually develop resistance after an average of 1 year since treatment start. Acquired resistance is defined as evidence of clinical progression after initial clinical benefit. Several distinct mechanisms of resistance have been reported in the literature. In approximately one-third of resistant cases, tumors have acquired a secondary mutation within the ALK tyrosine kinase domain. The most common resistance mutation to crizotinib is the gatekeeper L1196M mutation, followed by the G1269A mutation. The ALK1151Tins and G1202R mutations are notable since they confer high-level resistance to crizotinib as well as to next-generation ALK inhibitors such as ceritinib. Other mutations described in ceritinib-resistant tissues include F1174C/V. A novel gatekeeper mutation V1180L and another mutation I1171T/N/S were identified that conferred resistance to both alectinib and crizotinib but remained sensitive to ceritinib and other next-generation ALK inhibitors.

A second mechanism of crizotinib resistance is amplification of the ALK fusion gene. This can occur alone or in combination with a secondary resistance mutation. Finally, a number of alternative or bypass signaling pathways mediate resistance to crizotinib. Bypass tracks described so far in patients with ALK-positive NSCLC with acquired resistance to crizotinib include the development of EGFR or KRAS mutations or activation of WT EGFR, HER2-, or KIT-receptors. Conversely, activated MET signaling has been shown to potentially mediate resistance to alectinib but not to crizotinib, with the latter demonstrating clinical efficacy anecdotally. Using patient-derived specimens, Crystal et al performed a pharmacological screen to determine effective drug combinations in the setting of acquired resistance. The combination of ALK and MEK or Src inhibitors were identified. This knowledge underlies the rationale to develop next-generation compounds and/or to combine therapies to overcome resistance. Moreover, in the context of recognized intratumor heterogeneity and dynamic expression of immune checkpoint modulators in ALK-positive NSCLC, combination trials of immunotherapies with ALK inhibitors for NSCLC are also foreseen in the future to overcome or delay resistance mechanisms to monotherapy.
Additional ALK inhibitors currently in clinical development

Various next-generation ATP-competitive ALK inhibitors are in clinical development. AP26113 is a dual ALK/EGFR inhibitor that has activity against EGFR T790M in cell and mouse models of NSCLC. ASP3026 demonstrates activity against ALK mutants F1174L, R1275Q, and L1196M. Acquired resistance cell line models to ASP3026 demonstrated the presence of various secondary point mutations (G1128S, C1156F, I1171N/T, F1174I, N1178H, E1210K, and C1156F/D1203N), which were variably sensitive to ceritinib, alectinib, and AP26113 depending on the specific mutation. PF-06463922, a highly potent-selective inhibitor of both ALK and ROS1, demonstrated activity against all mutation types. Indeed, it has the distinctive profile of activity against G1202R, in addition to L1196M and G11269A, in low nanomolar concentrations. RXDX-101 also inhibits tropomyosin-related kinase-A (TRK-A), TRK-B, and TRK-C in addition to ALK and ROS1. It has activity against the crizotinib-resistant ALK mutants L1196M and C1156Y. Another agent X-396 also has activity against these two mutations.

Table 1 and 2 list a summary of their clinical profile to date.

Inhibition of Hsp90 represents an interesting approach for treating ALK-positive NSCLC. Hsp90 is a molecular chaperone that assists in proper protein folding, stabilization, and function. It has been observed that many of the proteins to which it binds are involved in signaling pathways required for oncogenesis, leading to the development and study of Hsp90 inhibitors in cancer treatment.

Sequist et al conducted a Phase II trial studying IPI-504, a potent inhibitor of Hsp-90, in patients with advanced NSCLC who had progressed on EGFR inhibitor therapy. The study recruited 76 patients where five demonstrated a PR to IPI-504, out of which three patients were identified with ALK mutations.

Post hoc analysis of a Phase II study with ganetespib showed significant efficacy in ALK-translocated NSCLC. The trial enrolled 99 patients with NSCLC into three cohorts based on mutation status: EGFR-mutant, KRAS-mutant, or WT for both EGFR and KRAS. Eight of 23 patients in the WT cohort subsequently had EML4-ALK mutations identified.

<table>
<thead>
<tr>
<th>Trial</th>
<th>Year</th>
<th>Treatment regimen</th>
<th>Number of patients</th>
<th>Response rate (95% CI)</th>
<th>P-value</th>
<th>OS (mo) (95% CI)</th>
<th>P-value</th>
<th>PFS (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROFILE 1001 (expanded cohort)</td>
<td>2012</td>
<td>Crizotinib</td>
<td>143</td>
<td>60.8% (52.3–68.9)</td>
<td></td>
<td>9.7 mo (5.7–12.8)</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>PROFILE 1007</td>
<td>2013</td>
<td>Crizotinib or docetaxel</td>
<td>173</td>
<td>65% (57–72)</td>
<td>&lt;0.001</td>
<td>7.7 mo (6–8.8)</td>
<td>0.001</td>
<td>20.3 mo (18.1–NR)</td>
<td>0.54</td>
</tr>
<tr>
<td>PROFILE 1014</td>
<td>2014</td>
<td>Pemetrexed or carboplatin or cisplatin</td>
<td>174</td>
<td>20% (14–26)</td>
<td>0.001</td>
<td>3.0 mo (2–4.3)</td>
<td>0.001</td>
<td>22.8 mo (18.6 mo – NR)</td>
<td>0.18</td>
</tr>
</tbody>
</table>

Abbreviations: OS, overall survival; mo, months; NR, not reached.
this subset, four patients demonstrated a PR, three had stable disease, and one had progressive disease on treatment.83

Hsp90 inhibitors such as ganetespib have been shown to possess preclinical activity in crizotinib-resistant models of ALK-positive NSCLC in whom resistance was sustained by the presence of “ALK-dominant” mechanisms (ie, secondary point mutations in the ALK kinase domain as well as ALK gene amplification).84 In addition, HSP90 inhibition holds the potential to be effective regardless of the type of secondary ALK mutation in contrast to the next-generation ALK inhibitors discussed earlier, which have varying efficacy depending on the mutation type. Phase II trials are currently being conducted to evaluate various Hsp90-inhibitor, either as monotherapy or in combination with an ALK inhibitor in either ALK inhibitor-naïve or -resistant population (NCT01712217, NCT01752400).

Conclusion

Crizotinib, an ALK inhibitor, has now been proven to be the preferred first-line therapy for ALK-positive NSCLC over platinum-based chemotherapy. FISH is currently considered as the gold standard testing modality for detecting ALK-positive NSCLC. Hsp90 inhibitors such as ganetespib have been shown to possess preclinical activity in crizotinib-resistant models of ALK-positive NSCLC in whom resistance was sustained by the presence of “ALK-dominant” mechanisms (ie, secondary point mutations in the ALK kinase domain as well as ALK gene amplification). In addition, HSP90 inhibition holds the potential to be effective regardless of the type of secondary ALK mutation in contrast to the next-generation ALK inhibitors discussed earlier, which have varying efficacy depending on the mutation type. Phase II trials are currently being conducted to evaluate various Hsp90-inhibitor, either as monotherapy or in combination with an ALK inhibitor in either ALK inhibitor-naïve or -resistant population (NCT01712217, NCT01752400).

Disclosure

The authors report no conflicts of interest in this work.

References


Table 2 Selected ALK inhibitors currently in the clinic or under clinical development

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Current phase</th>
<th>Toxicity</th>
<th>Response Crizotinib-naïve</th>
<th>Response Crizotinib-resistant</th>
<th>CNS response Crizotinib-naïve</th>
<th>CNS response Crizotinib-resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crizotinib (PF-02341066)</td>
<td>III</td>
<td>Visual disturbances, nausea, vomiting, constipation, edema</td>
<td>–</td>
<td>–</td>
<td>Untreated: Intracranial DCR – 56% (95% CI, 46–66) Intracranial TTP: 6.7–16.4 mo85 Treated with radiotherapy: Intracranial DCR – 62% (95% CI, 54–70) mTTP: 13.2 mo (95% CI, 9.9–NR)85 ( ORR ) 75% (95% CI, 19.4–99.4)81 ( ORR ) 40% (95% CI, 12.2–73.8)81</td>
<td></td>
</tr>
<tr>
<td>Certinib (LDK378)</td>
<td>II/III</td>
<td>Diarrhea, elevated transaminases</td>
<td>ORR – 41/59 (66%)41 mPFS: not reached41</td>
<td>ORR – 67/121 (54.6%)41 mPFS: 6.9 mo41</td>
<td>Phase II: ORR – 43/46 (93.5%)46</td>
<td>Phase I/II: ORR – 24/44 (55%), SD – 16/44 (36%)47</td>
</tr>
<tr>
<td>Alectinib (CH542802/RO542802)</td>
<td>II/III</td>
<td>Nausea, fatigue, myalgias, neutropenia, elevated CPK</td>
<td>Phase I: ORR – 43/46 (93.5%)46</td>
<td>Phase I/II: ORR – 24/44 (55%), SD – 16/44 (36%)47</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>AP26113</td>
<td>II</td>
<td>Nausea, fatigue, diarrhea</td>
<td>–</td>
<td>ORR – 24/38 (63%)48</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ASP-3026</td>
<td>IB</td>
<td>Nausea, vomiting, constipation, abdominal pain</td>
<td>–</td>
<td>mPFS: 47 wk48</td>
<td>PR: 7/15 (49%), SD: 8/15 (50%)47</td>
<td>–</td>
</tr>
<tr>
<td>X-396</td>
<td>II/II</td>
<td>N/A</td>
<td>13 ALK+: 3 crizotinib-naive and 10 crizotinib-resistant – among 6 ALK + patients; SD 17% and PR 83% (unsure of crizotinib-naive or -resistant)78</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: TTP, time to progression; CI, confidence interval; ORR, overall response rate; SD, standard deviation; PFS, progression-free survival; mPFS, median progression-free survival; ALK, anaplastic lymphoma kinase; CNS, central nervous system; CPK, creatine phosphokinase; wk, weeks; mo, months; DCR, disease control rate; NR, not reached; mTTP, median time to progression; N/A, not available; PD, progressive disease.


Lung Cancer: Targets and Therapy 2015:6


62. Ou SH, Greebowe J, Khan ZU, et al. I1171N missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to certinib. Lung Cancer. 2015;88(2):231–234.


